The Relative Antithrombotic Effectiveness of Heparin, a Low Molecular Weight Heparin, and a Pentasaccharide Fragment in an Animal Model

D P Thomas; R E Merton; E Gray; T W Barrowcliffe

doi:10.1055/s-0038-1646559

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1989; 61(02): 204-207
DOI: 10.1055/s-0038-1646559

Original Article

Schattauer GmbH Stuttgart

The Relative Antithrombotic Effectiveness of Heparin, a Low Molecular Weight Heparin, and a Pentasaccharide Fragment in an Animal Model

Authors

D P Thomas

The National Institute for Biological Standards and Control, Potters Bar, Herts., UK
R E Merton

The National Institute for Biological Standards and Control, Potters Bar, Herts., UK
E Gray

The National Institute for Biological Standards and Control, Potters Bar, Herts., UK
T W Barrowcliffe

The National Institute for Biological Standards and Control, Potters Bar, Herts., UK

Abstract

PDF Download

Summary

The antithrombotic efficacy of unfractionated heparin (UFH), a low molecular weight heparin (LMWH) and a synthetic pentasaccharide (PENTA) has been compared in an animal model for stasis thrombosis. We have also compared the relative ability of these three agents to impair thrombin generation in vitro and in vivo, and measured their effects on anti-Xa activity and thrombin clotting times. UFH, LMWH and PENTA all had the capacity to impair thrombogenesis, although there were marked differences in their relative effectiveness. Reduction of thrombin generation to 20% of control values was closely correlated with the prevention of thrombosis after 20 minutes’ stasis, but this was only achieved with UFH. The same dry weight dose of LMWH or PENTA reduced thrombin generation to about half control values, and neither significantly impaired thrombus formation after 20 minutes’ stasis. Impaired thrombin generation correlated better than anti-Xa activity with prevention of stasis thrombosis. In this model, UFH was clearly superior to LMWH and PENTA as an antithrombotic agent.

Keywords

Heparin - Low molecular weight heparin - Pentasaccharide - Thrombosis - Thrombin generation

PDF (219 kb)

References

References
1 Hemker HC. The mode of action of heparin in plasma. In: Thrombosis and Haemostasis. Verstraete M, Vermylen J, Lijnen R, Arnout J. (eds) Leuven University Press; Leuven: 1987. pp 17-36
2 Hirsh J, Ofosu FA, Levine M. The development of low molecular weight heparins for clinical use. In: Thrombosis and Haemostasis. Verstraete M, Vermylen J, Lijnen R, Arnout J. (eds) Leuven University Press; Leuven: 1987. pp 325-348
3 Barrowcliffe TW, Curtis AD, Johnson EA, Thomas DP. An international standard for low molecular weight heparin. Thromb Haemostas 1988; 60: 1-7
4 Petitou M, Duchaussoy P, Lederman I, Choay J, Jacquinet JC, Sinay P, Torri G. Synthesis of heparin fragments: a methyl alpha-pentaside with high affinity for antithrombin III. Carbohyd Res 1987; 167: 67-75
5 Merton RE, Thomas DP. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents. Thromb Haemostas 1987; 58: 839-842
6 Thomas DP, Merton RE. A low molecular weight heparin compared with unfractionated heparin. Thromb Res 1982; 28: 343-350
7 Eggleton CA, Barrowcliffe TW, Merton RE, Thomas DP. In vitro and in vivo studies of the anti-Xa activity of heparin. Thromb Res 1981; 34: 319-338
8 Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thromb Haemostas 1982; 47: 244-248
9 Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-485
10 Ockelford PA, Carter CJ, Mitchell L, Hirsh J. Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb Res 1982; 28: 401-409
11 Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 1987; 46: 187-198
12 Walenga JM, Bora L, Petitou M, Samama M, Fareed J, Choay J. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-Factor Xa activity. Thromb Res 1988; 51: 23-33
13 Walenga JM. Factor Xa inhibition in mediating antithrombotic actions: application of a synthetic heparin pentasaccharide. Doctoral Thesis Universite Paris: VI 06/1987. p 184
14 Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis inducing ability in human serum. J Appl Physiol 1959; 14: 943-946
15 Thomas DP, Merton RE, Barrowcliffe TW. The relative efficacy of heparin and related glycosaminoglycans as antithrombotic drugs. In: Structure and Activities of Heparin and Related Glycosaminoglycans as Antithrombotic Drugs Ofosu FA, Danishefsky I, Hirsh J. (eds) Annals of the New York Academy of Sciences; 1989. (in press)
16 Fernandez FA, Buchanan MR, Hirsh J, Fenton JW, Ofosu FA. Catalysis of thrombin inhibition provides an index for estimating antithrombotic potential of glycosaminoglycans in rabbits. Thromb Haemostas 1987; 57: 286-293
17 van Rijn JL M L, Trillou M, Mardiguian J, Tobelem G, Caen J. Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics Thromb Res 1987; 45: 211-222
18 Thomas DP. Current status of low molecular weight heparin. Thromb Haemostas 1986; 56: 241-242